![Oakes Benjamin Aih24](https://aspenideasfestival.imgix.net/2c71ec85-98ce-4581-bf39-a9229e04f884/Oakes_Benjamin_AIH24.jpeg?auto=compress%2Cformat&fit=min&fm=jpg&h=290&q=80&rect=0%2C335%2C2667%2C2670&w=290)
Benjamin Oakes
Co-Founder and CEO, Scribe Therapeutics
Benjamin Oakes is the co-founder and CEO of Scribe Therapeutics, a genetic medicines company unlocking the potential of CRISPR to transform human health. Previously, Oakes was an Innovative Genomics Institute Entrepreneurial Fellow, received a Ph.D. in molecular and cellular biology from the University of California, Berkeley, and worked in the lab of Nobel laureate and CRISPR co-inventor Jennifer Doudna. Oakes and his Scribe team pioneered CRISPR by Design™, a data-driven design and engineering process, to enable a new era of in vivo CRISPR-based standard of care treatments for patients with highly prevalent diseases.
Previously
![CRISPR 2.0, the Next Generation](https://aspenideasfestival.imgix.net/664fa430-dd44-42c1-9e79-96c5a63c1fc0/53807106830_a6524a26eb_o.jpg?auto=compress%2Cformat&fit=min&fm=jpg&h=225&q=80&rect=0%2C0%2C5800%2C3264&w=400)
History was made this year when the first FDA-approved CRISPR-based gene editing therapy became available to patients, designed to cure sickle cell anemia. That represents gr...